Skip to main content
SEPN
NASDAQ Life Sciences

Septerna Names SEP-204 Development Candidate for Graves' Disease and TED; Phase 1 Set for Q1 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$43.7
Mkt Cap
$2.04B
52W Low
$17.55
52W High
$51.1
52W Position info
149% above low
Off High info
14% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SEPN has more than doubled off its 52-week low of $17.55.

Summary

Septerna selected SEP-204, an oral TSHR inhibitor for Graves' disease and thyroid eye disease, as a development candidate and reported supportive preclinical data, with a Phase 1 trial planned to start in Q1 2027.


Key Events · Product Development and Regulatory · SEPN

  • SEP-204 Named Development Candidate

    Septerna selected SEP-204, an oral small molecule TSHR negative allosteric modulator, as its development candidate for Graves' disease and thyroid eye disease.

  • Preclinical Data Show Reversal of Disease Signs

    In a TSAb-driven mouse model, SEP-204 normalized T4 and reduced thyroid enlargement and orbital proptosis within 2 weeks; it is >1000x selective for TSHR over FSHR and LHR.

  • Phase 1 Start Planned for Q1 2027

    A Phase 1 trial in healthy volunteers is anticipated to begin in the first quarter of 2027; a projected human half-life of ~20-40 hours supports once-daily oral dosing.

  • Cash Runway Into 2029 Reiterated

    The updated corporate presentation states cash runway is expected to support operating plans at least into 2029, alongside lead programs SEP-479 (Phase 1 data expected Q1 2027) and SEP-631.


Analysis · SEPN · Life Sciences

Septerna has added a third wholly-owned clinical-stage asset: SEP-204, an oral TSHR negative allosteric modulator targeting Graves' disease and thyroid eye disease, a market of more than 2 million US Graves' patients where no new treatments have been approved in decades. For a first-in-class program, the preclinical package is credible: over 1000x selectivity versus related receptors, T4 normalization and reversal of thyroid enlargement and eye proptosis in a TSAb-driven mouse model, and a projected 20-40 hour human half-life that supports once-daily oral dosing. Value hinges on the Phase 1 start planned for Q1 2027, still roughly a quarter away and carrying the usual risk that preclinical findings do not translate to patients. The accompanying presentation also reiterates a cash runway into at least 2029, so this is pipeline expansion rather than a financing event.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SEPN was trading at $43.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $17.55 to $51.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SEPN - Latest Insights

SEPN
Nov 09, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $50.74
Real-time Price: $39.45 info
Change: -$11.29 (-22%) info
Market Cap: $1.876B info
SEPN
Nov 09, 2026, 4:03 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.74
Real-time Price: $39.45 info
Change: -$11.29 (-22%) info
Market Cap: $1.876B info
SEPN
Aug 14, 2026, 5:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $45.39
Real-time Price: $39.45 info
Change: -$5.94 (-13%) info
Market Cap: $1.876B info
SEPN
Aug 12, 2026, 6:55 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $48.19
Real-time Price: $39.45 info
Change: -$8.74 (-18%) info
Market Cap: $1.876B info
SEPN
Jun 22, 2026, 4:16 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $34.85
Real-time Price: $39.45 info
Change: +$4.60 (+13%) info
Market Cap: $1.876B info